Abbott vs. Dexcom: Competition in CGM Market
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 hours ago
0mins
Source: NASDAQ.COM
- Market Leadership: Abbott leads the continuous glucose monitoring (CGM) market with its FreeStyle Libre product line, which surpassed five million patient installations three years ago, demonstrating strong market penetration, while Dexcom, despite outperforming over the past decade, has yet to reach this milestone.
- Diversification Advantage: Abbott's business spans medical devices, diagnostics, nutrition, and pharmaceuticals, allowing it to maintain stable revenue and earnings growth, while also providing the financial resources for continued investment in the CGM market, enhancing its competitive position.
- Acquisition for Market Expansion: Abbott's $21 billion acquisition of Exact Sciences allows entry into the cancer diagnostics market, with Cologuard serving as a non-invasive colorectal cancer screening tool targeting millions of eligible individuals yet to be tested, showcasing its potential for expansion in healthcare.
- Risk vs. Reward: While Dexcom shows stronger revenue growth, its lack of diversification poses higher risks, especially if the CGM market is impacted by GLP-1 medications, whereas Abbott's diversified business model enables quicker recovery, making it more suitable for risk-averse investors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABT
Wall Street analysts forecast ABT stock price to rise
19 Analyst Rating
17 Buy
2 Hold
0 Sell
Strong Buy
Current: 96.810
Low
136.00
Averages
148.11
High
169.00
Current: 96.810
Low
136.00
Averages
148.11
High
169.00
About ABT
Abbott Laboratories is a global healthcare company. The Company’s principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. Its segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. Diagnostic Products segment is involved in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. Nutritional Products segment is engaged in the worldwide sales of a broad line of adult and pediatric nutritional products. Medical Devices segment is involved in the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. It serves people in more than 160 countries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Abbott vs. Dexcom: The CGM Market Showdown
- Market Leadership: Abbott's FreeStyle Libre has surpassed five million patients in the past three years, becoming the best-selling medical device of all time in dollar sales, showcasing its strong leadership in the CGM market, while Dexcom has yet to reach this milestone.
- Diversification Advantage: Abbott's business spans medical devices, diagnostics, nutrition, and pharmaceuticals, allowing it to achieve stable revenue and earnings growth with market-leading devices like MitraClip, while its acquisition in the cancer diagnostics market provides new growth opportunities.
- Competitive Dynamics: Although Dexcom has shown faster revenue growth in the CGM market, its lack of diversification poses higher risks, especially if the CGM market is impacted by GLP-1 medications, whereas Abbott's diversified business model enables quicker recovery.
- Investment Choice: For risk-averse investors, Abbott is a better choice due to its stable dividends and market leadership, while Dexcom appeals more to risk-tolerant investors seeking high growth.
See More
Abbott vs. Dexcom: Competition in CGM Market
- Market Leadership: Abbott leads the continuous glucose monitoring (CGM) market with its FreeStyle Libre product line, which surpassed five million patient installations three years ago, demonstrating strong market penetration, while Dexcom, despite outperforming over the past decade, has yet to reach this milestone.
- Diversification Advantage: Abbott's business spans medical devices, diagnostics, nutrition, and pharmaceuticals, allowing it to maintain stable revenue and earnings growth, while also providing the financial resources for continued investment in the CGM market, enhancing its competitive position.
- Acquisition for Market Expansion: Abbott's $21 billion acquisition of Exact Sciences allows entry into the cancer diagnostics market, with Cologuard serving as a non-invasive colorectal cancer screening tool targeting millions of eligible individuals yet to be tested, showcasing its potential for expansion in healthcare.
- Risk vs. Reward: While Dexcom shows stronger revenue growth, its lack of diversification poses higher risks, especially if the CGM market is impacted by GLP-1 medications, whereas Abbott's diversified business model enables quicker recovery, making it more suitable for risk-averse investors.
See More
Investment Opportunities in Healthcare Stocks
- Market Volatility Impact: The stock market has faced increased volatility recently, with the S&P 500 shifting from gains to losses; although the market has rebounded, many stocks remain at lower valuation levels, reflecting ongoing investor concerns about the economy and interest rate policies.
- Da Vinci Surgical Robot: Intuitive Surgical's Da Vinci surgical robot, priced over $1 million, offers hospitals various options and boasts 150 design innovations and 10,000 times the computing power of its predecessor, helping the company maintain market leadership with a 19% revenue growth in the last quarter.
- Abbott Laboratories Diversification: Abbott Laboratories achieves diversification through its four business units—medical devices, diagnostics, pharmaceuticals, and nutrition—ensuring that when one segment faces challenges, others can provide support, enhancing overall company safety.
- Attractive Dividend Growth: As a 'Dividend King' that has raised its dividend for 50 consecutive years, Abbott's current stock price at 17 times forward earnings, down from 22 times in early 2026, makes it a compelling healthcare stock to invest in following recent market turbulence.
See More
Investment Opportunities in Healthcare Stocks
- Market Volatility Impact: The stock market has experienced volatility recently, with the S&P 500 shifting between gains and losses, leading to increased investor concerns about the economy, interest rates, and geopolitical conflicts, which have dampened stock demand.
- Intuitive Surgical Earnings Growth: Intuitive Surgical (NASDAQ: ISRG) reported a 19% revenue increase and a 17% rise in Da Vinci procedures in the latest quarter, demonstrating its market leadership in robotic surgery and a strong recurring revenue stream.
- Abbott Laboratories Diversification Advantage: Abbott (NYSE: ABT) benefits from its diversified business model across medical devices, diagnostics, pharmaceuticals, and nutrition, which has provided revenue stability, particularly during the pandemic when diagnostics surged to offset declines in medical devices.
- Dividend Growth Appeal: As a
See More
Analysis of High-Yield Stock Investment Opportunities
- AbbVie's Appeal: AbbVie boasts a forward dividend yield of 3.3%, slightly above the S&P 500's 1.1%, and its status as a 'Dividend King' with 53 consecutive years of increases attracts both value and income investors, with solid growth expected ahead.
- Enbridge's Stability: Enbridge offers a robust 5.4% dividend yield and has increased its dividend for 31 consecutive years, operating over 18,000 miles of crude oil and 19,000 miles of natural gas pipelines, ensuring stability and visible growth opportunities in the energy sector.
- Realty Income's Growth Potential: Realty Income provides a 5% dividend yield and has also raised its dividend for 31 years, with a high occupancy rate of 98.9% and a diversified tenant base, positioning it well for growth, particularly in the European market.
- Market Environment Challenges: While the S&P 500 has rebounded after volatility, many growth stocks remain unstable, and rising bond yields necessitate a focus on the Federal Reserve's policy direction to capitalize on high-yield stock investment opportunities.
See More
Analysis of High-Yield Stock Investment Opportunities
- AbbVie's Dividend King Status: AbbVie boasts a forward dividend yield of 3.3%, slightly above the S&P 500's 1.1%, and its impressive 53-year streak of dividend increases positions it as a Dividend King, appealing to both value and income investors alike.
- Enbridge's Stability and Growth Potential: With a dividend yield of 5.4% and a 31-year history of increases, Enbridge operates over 18,000 miles of crude oil and 19,000 miles of natural gas pipelines, providing stable cash flow and visible growth opportunities, with around $50 billion identified for the next decade.
- Realty Income's Monthly Dividend Advantage: Realty Income offers a 5% dividend yield and has also increased its dividend for 31 consecutive years, with its unique monthly payment structure providing investors with more frequent cash flow, supported by a high occupancy rate of 98.9% that demonstrates resilience during economic downturns.
- Market Expansion and Competitive Edge: Realty Income's promising opportunities in Europe, with a total addressable market of $8.5 trillion and limited competition, are expected to drive sustained growth, while its diversified tenant base enhances its risk resilience.
See More
Abbott vs. Dexcom: The CGM Market Showdown
- Market Leadership: Abbott's FreeStyle Libre has surpassed five million patients in the past three years, becoming the best-selling medical device of all time in dollar sales, showcasing its strong leadership in the CGM market, while Dexcom has yet to reach this milestone.
- Diversification Advantage: Abbott's business spans medical devices, diagnostics, nutrition, and pharmaceuticals, allowing it to achieve stable revenue and earnings growth with market-leading devices like MitraClip, while its acquisition in the cancer diagnostics market provides new growth opportunities.
- Competitive Dynamics: Although Dexcom has shown faster revenue growth in the CGM market, its lack of diversification poses higher risks, especially if the CGM market is impacted by GLP-1 medications, whereas Abbott's diversified business model enables quicker recovery.
- Investment Choice: For risk-averse investors, Abbott is a better choice due to its stable dividends and market leadership, while Dexcom appeals more to risk-tolerant investors seeking high growth.
See More
Abbott vs. Dexcom: Competition in CGM Market
- Market Leadership: Abbott leads the continuous glucose monitoring (CGM) market with its FreeStyle Libre product line, which surpassed five million patient installations three years ago, demonstrating strong market penetration, while Dexcom, despite outperforming over the past decade, has yet to reach this milestone.
- Diversification Advantage: Abbott's business spans medical devices, diagnostics, nutrition, and pharmaceuticals, allowing it to maintain stable revenue and earnings growth, while also providing the financial resources for continued investment in the CGM market, enhancing its competitive position.
- Acquisition for Market Expansion: Abbott's $21 billion acquisition of Exact Sciences allows entry into the cancer diagnostics market, with Cologuard serving as a non-invasive colorectal cancer screening tool targeting millions of eligible individuals yet to be tested, showcasing its potential for expansion in healthcare.
- Risk vs. Reward: While Dexcom shows stronger revenue growth, its lack of diversification poses higher risks, especially if the CGM market is impacted by GLP-1 medications, whereas Abbott's diversified business model enables quicker recovery, making it more suitable for risk-averse investors.
See More
Investment Opportunities in Healthcare Stocks
- Market Volatility Impact: The stock market has faced increased volatility recently, with the S&P 500 shifting from gains to losses; although the market has rebounded, many stocks remain at lower valuation levels, reflecting ongoing investor concerns about the economy and interest rate policies.
- Da Vinci Surgical Robot: Intuitive Surgical's Da Vinci surgical robot, priced over $1 million, offers hospitals various options and boasts 150 design innovations and 10,000 times the computing power of its predecessor, helping the company maintain market leadership with a 19% revenue growth in the last quarter.
- Abbott Laboratories Diversification: Abbott Laboratories achieves diversification through its four business units—medical devices, diagnostics, pharmaceuticals, and nutrition—ensuring that when one segment faces challenges, others can provide support, enhancing overall company safety.
- Attractive Dividend Growth: As a 'Dividend King' that has raised its dividend for 50 consecutive years, Abbott's current stock price at 17 times forward earnings, down from 22 times in early 2026, makes it a compelling healthcare stock to invest in following recent market turbulence.
See More
Investment Opportunities in Healthcare Stocks
- Market Volatility Impact: The stock market has experienced volatility recently, with the S&P 500 shifting between gains and losses, leading to increased investor concerns about the economy, interest rates, and geopolitical conflicts, which have dampened stock demand.
- Intuitive Surgical Earnings Growth: Intuitive Surgical (NASDAQ: ISRG) reported a 19% revenue increase and a 17% rise in Da Vinci procedures in the latest quarter, demonstrating its market leadership in robotic surgery and a strong recurring revenue stream.
- Abbott Laboratories Diversification Advantage: Abbott (NYSE: ABT) benefits from its diversified business model across medical devices, diagnostics, pharmaceuticals, and nutrition, which has provided revenue stability, particularly during the pandemic when diagnostics surged to offset declines in medical devices.
- Dividend Growth Appeal: As a
See More
Analysis of High-Yield Stock Investment Opportunities
- AbbVie's Appeal: AbbVie boasts a forward dividend yield of 3.3%, slightly above the S&P 500's 1.1%, and its status as a 'Dividend King' with 53 consecutive years of increases attracts both value and income investors, with solid growth expected ahead.
- Enbridge's Stability: Enbridge offers a robust 5.4% dividend yield and has increased its dividend for 31 consecutive years, operating over 18,000 miles of crude oil and 19,000 miles of natural gas pipelines, ensuring stability and visible growth opportunities in the energy sector.
- Realty Income's Growth Potential: Realty Income provides a 5% dividend yield and has also raised its dividend for 31 years, with a high occupancy rate of 98.9% and a diversified tenant base, positioning it well for growth, particularly in the European market.
- Market Environment Challenges: While the S&P 500 has rebounded after volatility, many growth stocks remain unstable, and rising bond yields necessitate a focus on the Federal Reserve's policy direction to capitalize on high-yield stock investment opportunities.
See More
Analysis of High-Yield Stock Investment Opportunities
- AbbVie's Dividend King Status: AbbVie boasts a forward dividend yield of 3.3%, slightly above the S&P 500's 1.1%, and its impressive 53-year streak of dividend increases positions it as a Dividend King, appealing to both value and income investors alike.
- Enbridge's Stability and Growth Potential: With a dividend yield of 5.4% and a 31-year history of increases, Enbridge operates over 18,000 miles of crude oil and 19,000 miles of natural gas pipelines, providing stable cash flow and visible growth opportunities, with around $50 billion identified for the next decade.
- Realty Income's Monthly Dividend Advantage: Realty Income offers a 5% dividend yield and has also increased its dividend for 31 consecutive years, with its unique monthly payment structure providing investors with more frequent cash flow, supported by a high occupancy rate of 98.9% that demonstrates resilience during economic downturns.
- Market Expansion and Competitive Edge: Realty Income's promising opportunities in Europe, with a total addressable market of $8.5 trillion and limited competition, are expected to drive sustained growth, while its diversified tenant base enhances its risk resilience.
See More
